Magnesium in acute and chronic brain injury: an update.
While brain free magnesium levels have been shown to decline in a number of acute and chronic brain pathologies, the mechanisms of such decline and the potential for magnesium administration as a therapeutic intervention are still unclear. In acute brain injury, magnesium therapy has failed in recent clinical trials of trauma, presumably because of an intact blood brain barrier at the time of administration reducing central penetration. Under such conditions, magnesium's peripheral effects on cardiovascular parameters may dominate over the central, and potentially neuroprotective, effects of the compound. In contrast, magnesium has been demonstrated to be beneficial in lacunar strokes, albeit that recent animal studies indicate that this effect is without any significant reduction of lesion size. Postnatal magnesium has also been shown to improve neurological outcome in term neonates with perinatal asphyxia, although this may be limited to cases of mild to moderate brain injury; no effect is observed following severe brain injury. Prenatal magnesium has been reported to be beneficial for outcome in very preterm infants, although this may only be at low doses. Combination therapies are also showing promise in experimental studies, with combined magnesium and mild hypothermia as well as magnesium and polyethylene glycol proving effective in ischemic stroke and in spinal cord injury, respectively. With respect to chronic brain injury, recent results indicate that magnesium deficient mice are susceptible to developing Parkinson's disease, which is consistent with earlier findings that magnesium deficiency over a number of generations is associated with the development of Parkinson's disease. The latter was associated with the appearance of variants of the TRPM channels. Our recent studies have shown that Parkinson's disease is associated with reduced TRPM2 and TRPM7 channel mRNA expression. Taken together, a more complete picture is emerging of the role of magnesium in brain injury, its therapeutic potential as well the mechanisms associated with its decline.
Vink
Robert
R
Discipline of Pathology, School of Medical Sciences, University of Adelaide, Australia. Robert.Vink@adelaide.edu.au
Cook
Naomi L
NL
van den Heuvel
Corinna
C
D000818:Animals; D001930:Brain Injuries / Q000188:drug therapy* / Q000473:pathology*; D020208:Brain Injury, Chronic / Q000188:drug therapy / Q000473:pathology; D006801:Humans; D008274:Magnesium / Q000627:therapeutic use*; D015201:Meta-Analysis as Topic; D019636:Neurodegenerative Diseases / Q000188:drug therapy / Q000473:pathology; D018696:Neuroprotective Agents / Q000627:therapeutic use; D020521:Stroke / Q000188:drug therapy / Q000473:pathology
D018696:Neuroprotective Agents; D008274:Magnesium